A citation-based method for searching scientific literature

Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki. Mol Ther 2021
Times Cited: 8







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.
D F Stojdl, B Lichty, S Knowles, R Marius, H Atkins, N Sonenberg, J C Bell. Nat Med 2000
612
25

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
William S M Wold, Karoly Toth. Curr Gene Ther 2013
240
25


Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Andrew Stiff, Enrico Caserta, Douglas W Sborov, Gerard J Nuovo, Xiaokui Mo, Sarah Y Schlotter, Alessandro Canella, Emily Smith, Joseph Badway, Matthew Old,[...]. Mol Cancer Ther 2016
27
25

Counteracting CAR T cell dysfunction.
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, Stina L Wickström, Angel Cid-Arregui, Rolf Kiessling. Oncogene 2021
10
25

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
Edmund K Moon, Carmine Carpenito, Jing Sun, Liang-Chuan S Wang, Veena Kapoor, Jarrod Predina, Daniel J Powell, James L Riley, Carl H June, Steven M Albelda. Clin Cancer Res 2011
317
25

Clinical landscape of oncolytic virus research in 2020.
Nicholas Macedo, David M Miller, Rizwan Haq, Howard L Kaufman. J Immunother Cancer 2020
35
25

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
25

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
25

MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
Patrizia Leone, Eui-Cheol Shin, Federico Perosa, Angelo Vacca, Franco Dammacco, Vito Racanelli. J Natl Cancer Inst 2013
264
25


Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
Venkatesh Sivanandam, Christopher J LaRocca, Nanhai G Chen, Yuman Fong, Susanne G Warner. Mol Ther Oncolytics 2019
64
25

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
John A Craddock, An Lu, Adham Bear, Martin Pule, Malcolm K Brenner, Cliona M Rooney, Aaron E Foster. J Immunother 2010
313
25

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.
Nobuhiro Nishio, Iulia Diaconu, Hao Liu, Vincenzo Cerullo, Ignazio Caruana, Valentina Hoyos, Lisa Bouchier-Hayes, Barbara Savoldo, Gianpietro Dotti. Cancer Res 2014
158
25

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Keisuke Watanabe, Yanping Luo, Tong Da, Sonia Guedan, Marco Ruella, John Scholler, Brian Keith, Regina M Young, Boris Engels, Suvi Sorsa,[...]. JCI Insight 2018
97
25


Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.
Francesca Tucci, Samantha Scaramuzza, Alessandro Aiuti, Alessandra Mortellaro. Mol Ther 2021
8
12

Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
Albert M Maguire, Jean Bennett, Elena M Aleman, Bart P Leroy, Tomas S Aleman. Mol Ther 2021
12
12

Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Jerry R Mendell, Samiah A Al-Zaidy, Louise R Rodino-Klapac, Kimberly Goodspeed, Steven J Gray, Christine N Kay, Sanford L Boye, Shannon E Boye, Lindsey A George, Stephanie Salabarria,[...]. Mol Ther 2021
34
12

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.
Garima Sharma, Ashish Ranjan Sharma, Manojit Bhattacharya, Sang-Soo Lee, Chiranjib Chakraborty. Mol Ther 2021
16
12


Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Colby S Shemesh, Joy C Hsu, Iraj Hosseini, Ben-Quan Shen, Anand Rotte, Patrick Twomey, Sandhya Girish, Benjamin Wu. Mol Ther 2021
21
12


Applications of coxsackievirus A21 in oncology.
Stephen Bradley, Adam D Jakes, Kevin Harrington, Hardev Pandha, Alan Melcher, Fiona Errington-Mais. Oncolytic Virother 2014
45
12

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Federica Costa, Rosanna Vescovini, Valentina Marchica, Paola Storti, Laura Notarfranchi, Benedetta Dalla Palma, Denise Toscani, Jessica Burroughs-Garcia, Maria Teresa Catarozzo, Gabriella Sammarelli,[...]. Front Immunol 2021
2
50


Multiple myeloma.
Niels W C J van de Donk, Charlotte Pawlyn, Kwee L Yong. Lancet 2021
32
12

Oncolytic virotherapy for hematological malignancies.
Swarna Bais, Eric Bartee, Masmudur M Rahman, Grant McFadden, Christopher R Cogle. Adv Virol 2012
28
12

Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Kah-Whye Peng, Ahmet Dogan, Julie Vrana, Chunsheng Liu, Hooi T Ong, Shaji Kumar, Angela Dispenzieri, Allan B Dietz, Stephen J Russell. Am J Hematol 2009
41
12

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.
J D Robertson, K Nagesh, S N Jowitt, M Dougal, H Anderson, K Mutton, M Zambon, J H Scarffe. Br J Cancer 2000
134
12

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Jessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, Helena Jernberg Wiklund, Emma Eriksson, Angelica Loskog. Cancer Gene Ther 2020
11
12

Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.
Svjetlana Raus, Silvia Coin, Vladia Monsurrò. Korean J Hematol 2011
10
12

Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.
G Dotti, B Savoldo, S Takahashi, T Goltsova, M Brown, D Rill, C Rooney, M Brenner. Exp Hematol 2001
32
12

Curative one-shot systemic virotherapy in murine myeloma.
S Naik, R Nace, M J Federspiel, G N Barber, K-W Peng, S J Russell. Leukemia 2012
57
12

Reovirus as a novel oncolytic agent.
K L Norman, P W Lee. J Clin Invest 2000
83
12


Reovirus and tumor oncolysis.
Manbok Kim, Young-Hwa Chung, Randal N Johnston. J Microbiol 2007
32
12




Pathogenesis of myeloma bone disease.
G D Roodman. Leukemia 2009
233
12

Oncolytic Immunotherapy for Treatment of Cancer.
A Tsun, X N Miao, C M Wang, D C Yu. Adv Exp Med Biol 2016
7
14

The JAM family of junctional adhesion molecules.
Gianfranco Bazzoni. Curr Opin Cell Biol 2003
220
12

A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Douglas W Sborov, Gerard J Nuovo, Andrew Stiff, Thomas Mace, Gregory B Lesinski, Don M Benson, Yvonne A Efebera, Ashley E Rosko, Flavia Pichiorri, Michael R Grever,[...]. Clin Cancer Res 2014
51
12

Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
A Munguia, T Ota, T Miest, S J Russell. Gene Ther 2008
46
12

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
J-L Li, H-L Liu, X-R Zhang, J-P Xu, W-K Hu, M Liang, S-Y Chen, F Hu, D-T Chu. Gene Ther 2009
68
12

What is oncolytic virotherapy?
Julia V Cockle, Karen J Scott. Arch Dis Child Educ Pract Ed 2018
3
33

LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.
Danit Finkelshtein, Ariel Werman, Daniela Novick, Sara Barak, Menachem Rubinstein. Proc Natl Acad Sci U S A 2013
283
12




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.